The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6
Authors:
- 1 April 2015
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 359 (2) , 250-258
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation (81270598, 81473486, 31340009)
- National Public Health Grand Research Foundation (201202017)
- Natural Science Foundations of Shandong Province (2009ZRB14176, ZR2011HQ009, ZR2012HZ003)
- Technology Development Projects of Shandong Province (2010GSF10250, 2014GSF118021)
- Program of Shandong Medical Leading Talent
- Taishan Scholar Foundation of Shandong Province
This publication has 60 references indexed in Scilit:
- Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapiesPharmacology & Therapeutics, 2014
- Personalized medicine in CLL: Current status and future perspectivesCancer Letters, 2014
- Changes in the Treatment Landscape for Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapiesSeminars in Cancer Biology, 2014
- Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic optionsCancer Letters, 2013
- Therapeutic advancement of chronic lymphocytic leukemiaJournal of Hematology & Oncology, 2012
- Chemotherapeutic Resistance: Surviving Stressful SituationsCancer Research, 2011
- Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2Haematologica, 2010
- Chronic lymphocytic leukaemiaThe Lancet, 2008
- Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcomeBlood, 2001